BACKGROUND: Tajikistan, considered highly endemic area for hepatitis B virus (HBV) in a pre-vaccine era, introduced hepatitis B vaccine in 2002 and reported ≥80% coverage with three doses of hepatitis B vaccine (HepB3) since 2004. However, the impact of vaccine introduction has not been assessed. METHODS: We tested residual serum specimens from a 2010 national serosurvey for vaccine-preventable diseases in Tajikistan and assessed the prevalence of HBV infection across groups defined based on the birth cohorts' routine infant hepatitis B vaccination program implementation and HepB3 coverage achieved (≥80% versus <80%). Serosurvey participants were selected through stratified multi-stage cluster sampling among residents of all regions of Tajikistan aged 1-24 years. All specimens were tested for antibodies against HBV core antigen (anti-HBc) and those found positive were tested for HBV surface antigen (HBsAg). Seroprevalence and 95% confidence intervals were calculated and compared across subgroups using Satterthwaite-adjusted chi-square tests, accounting for the survey design and sampling weights. RESULTS: A total of 2188 samples were tested. Prevalence of HBV infection markers was lowest among cohorts with ≥80% HepB3 coverage (ages, 1-6 years): 2.1% (95% confidence interval, 1.1-4.3%) for anti-HBc, 0.4% (0.1-1.3%) for HBsAg, followed by 7.2% (4.1-12.4%) for anti-HBc and 2.1% (0.7-6.1%) for HBsAg among cohorts with <80% HepB3 coverage (ages, 7-8 years), by 12.0% (8.7-16.3%) for anti-HBc and 3.5% (2.2-5.6%) for HBsAg among children's cohorts not targeted for vaccination (ages, 9-14 years), and 28.9% (24.5-33.8%) for anti-HBc and 6.8% (4.5-10.1%) for HBsAg among unvaccinated adult cohorts (ages, 15-24 years). Differences across groups were significant (p<0.001, chi-square) for both markers. CONCLUSIONS: The present study demonstrates substantial impact of hepatitis B vaccine introduction on reducing HBV infections in Tajikistan. To achieve further progress in hepatitis B control, Tajikistan should maintain high routine coverage with hepatitis B vaccine, including birth dose. Published by Elsevier Ltd.
BACKGROUND: Tajikistan, considered highly endemic area for hepatitis B virus (HBV) in a pre-vaccine era, introduced hepatitis B vaccine in 2002 and reported ≥80% coverage with three doses of hepatitis B vaccine (HepB3) since 2004. However, the impact of vaccine introduction has not been assessed. METHODS: We tested residual serum specimens from a 2010 national serosurvey for vaccine-preventable diseases in Tajikistan and assessed the prevalence of HBV infection across groups defined based on the birth cohorts' routine infant hepatitis B vaccination program implementation and HepB3 coverage achieved (≥80% versus <80%). Serosurvey participants were selected through stratified multi-stage cluster sampling among residents of all regions of Tajikistan aged 1-24 years. All specimens were tested for antibodies against HBV core antigen (anti-HBc) and those found positive were tested for HBV surface antigen (HBsAg). Seroprevalence and 95% confidence intervals were calculated and compared across subgroups using Satterthwaite-adjusted chi-square tests, accounting for the survey design and sampling weights. RESULTS: A total of 2188 samples were tested. Prevalence of HBV infection markers was lowest among cohorts with ≥80% HepB3 coverage (ages, 1-6 years): 2.1% (95% confidence interval, 1.1-4.3%) for anti-HBc, 0.4% (0.1-1.3%) for HBsAg, followed by 7.2% (4.1-12.4%) for anti-HBc and 2.1% (0.7-6.1%) for HBsAg among cohorts with <80% HepB3 coverage (ages, 7-8 years), by 12.0% (8.7-16.3%) for anti-HBc and 3.5% (2.2-5.6%) for HBsAg among children's cohorts not targeted for vaccination (ages, 9-14 years), and 28.9% (24.5-33.8%) for anti-HBc and 6.8% (4.5-10.1%) for HBsAg among unvaccinated adult cohorts (ages, 15-24 years). Differences across groups were significant (p<0.001, chi-square) for both markers. CONCLUSIONS: The present study demonstrates substantial impact of hepatitis B vaccine introduction on reducing HBV infections in Tajikistan. To achieve further progress in hepatitis B control, Tajikistan should maintain high routine coverage with hepatitis B vaccine, including birth dose. Published by Elsevier Ltd.
Entities:
Keywords:
Hepatitis B immunization; Hepatitis B vaccine impact; Hepatitis B virus infections; Prevalence of HBsAg; Tajikistan; WHO European Region
Authors: Susan T Goldstein; Fangjun Zhou; Stephen C Hadler; Beth P Bell; Eric E Mast; Harold S Margolis Journal: Int J Epidemiol Date: 2005-10-25 Impact factor: 7.196
Authors: Y J Hutin; R Harpaz; J Drobeniuc; A Melnic; C Ray; M Favorov; P Iarovoi; C N Shapiro; B A Woodruff Journal: Int J Epidemiol Date: 1999-08 Impact factor: 7.196
Authors: Zhannat Z Nurgalieva; F Blaine Hollinger; David Y Graham; S Zhangabylova; Abai Zhangabylov Journal: World J Gastroenterol Date: 2007-02-28 Impact factor: 5.742
Authors: A Nardone; C G Anastassopoulou; H Theeten; B Kriz; I Davidkin; W Thierfelder; D O'Flanagan; B Bruzzone; J Mossong; H J Boot; D Butur; M Slaciková; M L C Panait; W Hellenbrand; H DE Melker; Z Sobotová; G Icardi; N Andrews; R G Pebody; P VAN Damme; G Kafatos; E Miller; A Hatzakis Journal: Epidemiol Infect Date: 2008-12-23 Impact factor: 2.451
Authors: Nino Khetsuriani; Mark A Pallansch; Shamsiddin Jabirov; Nargis Saparova; M Steven Oberste; Kathleen Wannemuehler; Pavel Ursu; Steve Wassilak; Rebecca Martin Journal: Vaccine Date: 2013-07-24 Impact factor: 3.641
Authors: Kyeong Hun Lee; Kyu Seok Shim; In Seok Lim; Soo Ahn Chae; Sin Weon Yun; Na Mi Lee; Young Bae Choi; Dae Yong Yi Journal: BMC Pediatr Date: 2017-07-14 Impact factor: 2.125
Authors: Tatiana Balaeva; Andrej M Grjibovski; Olga Samodova; Anatoly Sannikov; Elise Klouman Journal: Int J Environ Res Public Health Date: 2018-09-01 Impact factor: 3.390